Fig. 1From: Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody PamrevlumabStudy design. Eight-week pamrevlumab (FG-3019) treatment regimens were initiated before or after thoracic RT. Lungs were harvested at 18 or 30Â weeks for expression profiling. Two biologic replicate arrays were analyzed per treatment group at each time-point, and were compared as indicated (curved arrows)Back to article page